Postmenopausal Hormone Therapy and Risk of Stroke: Impact of the Route of Estrogen Administration and Type of Progestogen.

Stroke · 2016 · PMC4927222 · PMID 27256671

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

The risk was borderline significant for low-dose estrogen users and the greatest in those on high doses (OR, 1.39; 95% CI, 1.00–1.99; OR, 1.84; 95% CI, 1.02–3.30; and OR, 2.41; 95% CI, 1.43–4.07 for users of low, intermediate, and high doses, respectively).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.